FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.

18 Mar, 17:17 — 18 Mar, 17:17

Post Share

Sources

Showing 1 of 2 sources

cnbcMostly Factual3h ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.

Read full article →

Coverage Timeline

First report: Reuters · 18 Mar, 12:31|Full coverage: All 2 sources within 5h|Window: 5h

Left-leaningCenterRight-leaning

Reuters18 Mar, 12:31First to report

US FDA approves J&J's oral psoriasis pill - Reuters

5h later

cnbc18 Mar, 17:17Latest update

PERSPECTA

PERSPECTA

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Sources

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Coverage Timeline

US FDA approves J&J's oral psoriasis pill - Reuters

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Related Stories

Africa bears 25% of global TB burden despite declining deaths- WHO

Countries should consider vaccination for groups at highest risk of severe COVID-19 disease

Pubägaren Ash om smittoutbrottet: ”Folk vill inte gå ut”

Police investigate scam scheme involving fake Gesy messages

PERSPECTA